2025-04-25 12:00Financial Performance - The company's revenue for Q1 2025 was CNY 500,591,459.94, representing a 31.46% increase compared to CNY 380,804,271.07 in the same period last year[3] - The net profit attributable to shareholders was a loss of CNY 234,876,226.63, an improvement from a loss of CNY 283,029,082.76 year-over-year[3] - The net cash flow from operating activities was a negative CNY 24,331,196.50, significantly improved from a negative CNY 376,577,871.82 in the prior year[3] - Total revenue for Q1 2025 reached ¥500.59 million, a 31.5% increase from ¥380.80 million in Q1 2024[17] - Net loss for Q1 2025 was ¥259.59 million, an improvement compared to a net loss of ¥299.65 million in Q1 2024[18] - Basic and diluted earnings per share for Q1 2025 were both -¥0.24, an improvement from -¥0.29 in Q1 2024[18] Research and Development - R&D expenses totaled CNY 350,575,453.92, accounting for 70.03% of revenue, a decrease of 2.52 percentage points from the previous year[3] - Research and development expenses rose significantly to ¥350.58 million, up 27% from ¥276.29 million in the same period last year[17] - The company continues to focus on expanding its research and development efforts to enhance product offerings and market presence[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,897,069,766.80, a 1.07% increase from CNY 10,781,960,410.10 at the end of the previous year[4] - The company's total liabilities increased to RMB 5.228 billion from RMB 4.850 billion, indicating a rise in financial obligations[14] - The total equity attributable to shareholders decreased by 4.10% to CNY 5,620,244,628.63 from CNY 5,860,424,336.29[4] - The total equity attributable to shareholders decreased to RMB 5.620 billion from RMB 5.860 billion, showing a decline in shareholder equity[14] Market and Product Development - The company reported an increase in commercial drug sales, contributing to the rise in revenue[6] - The company's revenue growth during the reporting period was primarily driven by the sales of commercialized drugs, with the core product, Toripalimab injection (brand name: Tuoyi®/LOQTORZI®), achieving sales revenue of approximately RMB 447 million, representing a year-on-year increase of about 45.72%[10] - Toripalimab received conditional approval for routine use in treating unresectable or metastatic melanoma after previous systemic therapy failure, and a new indication for first-line treatment of advanced hepatocellular carcinoma in combination with Bevacizumab was approved[10] - During the reporting period, Toripalimab was approved for marketing by the Australian Therapeutic Goods Administration and the Singapore Health Sciences Authority, with 12 indications approved in mainland China, 10 of which are included in the national medical insurance catalog[11] - The company plans to accelerate the registration clinical trials for multiple products by 2025 and enhance the development and application of late-stage pipelines to ensure sustained revenue growth[12] - The company is committed to expanding its global market presence and increasing the accessibility of approved products and indications included in the national medical insurance catalog[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 29,429[8] - The top shareholder, HKSCC NOMINEES LIMITED, held 22.25% of the shares, totaling 219,291,210 shares[8]